Technology Licensing to Non-Traditional Partners

Abstract

The commercialization of technologies arising from university research depends on the ability of technology managers to find and contract with appropriate development partners. Substantial investment is required to bring new health-science technologies to market, and when such technologies appear to have limited commercial markets it can be difficult for technology managers to find any licensee willing to invest research and development dollars. Developments in the area of neglected diseases may open up new opportunities for licensing. Over the past decade, The Rockefeller Foundation and other donors have provided social venture capital to launch a number of non-profit ‘companies’ that have collectively raised more than $1 billion from philanthropic and government donors to support product development. These public–private partnerships (PPPs) support the development of drugs, vaccines and diagnostics to address diseases that predominantly afflict the poor, such as HIV/AIDS, tuberculosis and malaria. Today there are nearly a dozen such PPPs following business models, managing portfolios of candidate products (often in-licensed from academia), negotiating in-kind support from the private sector or engaging industry through contract research and development, and using intellectual property in creative ways to harness private-sector know-how while ensuring affordability and access. Academic research institutions have many functions, including those of educating the next generation of scientists, advancing and sharing knowledge and, perhaps, even improving the world. Any technology manager who ever imagined there might be priorities beyond income generation should consider these non-traditional partners.

Keywords

neglected diseases technology management innovation global health developing countries

Get full access to this article

View all access options for this article.

References

Boston Consulting Group (2003), Interim Evaluation of Harnessing the New Sciences: Final Report, prepared for The Rockefeller Foundation, 24 November.

Freire

M. C.

(2002), ‘Technology transfer's next frontier: Global health as a new bottom line’, Journal of the Association of University Technology Managers, Vol 14, pp 1–5

Industry and Higher Education, Vol 17, No 5, pp 309–311.

Mahoney

, ed (2003), Handbook of Best Practices for Management of Intellectual Property in Health Research and Development, Centre for Management of Intellectual Property in Health Research and Development, Oxford.

MSF (2001), Fatal Imbalance – the Crisis in Research and Development for Neglected Diseases, Access to Essential Medicines and the Drugs for Neglected Diseases Working Group, Médecins Sans Frontières, Geneva.

Nelsen

(2003), ‘The role of universities in assuring access in developing countries,’ Yale Journal of Health Policy, Law, and Ethics, Vol 3, pp 302–308.

Sander

Widdus

(2004), The Emerging Landscape of Public–Private Partnerships for Product Development, report prepared for workshop on ‘Combating Diseases Associated with Poverty: Financing Strategies for Product Development and the Potential Role of Public–Private Partnerships’, London, April.

Towse

, OHE Consulting (2004), ‘Estimates of the medium-term resource needs for development of pharmaceuticals for neglected diseases’, paper presented to the IPPPH Workshop, London, April.